

STENTYS Revenues for the First 9 Months of 2014 up 16.9%

PRINCETON, N.J. and PARIS - October 23, 2014 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and nine-months ended September 30, 2014.

- **Change in third-quarter and nine-month revenues***

€ thousand	9 months			Quarterly – 3 months		
	9 months 2014	9 months 2013	% change	Q3 2014	Q3 2013	% change
Revenues	2,812.4	2,406.6	+16.9%	876.5	768.0	+14.1%

* Data reviewed by the statutory auditors

STENTYS recorded revenues of €876.5 thousand over the third quarter of 2014, up 14.1% compared with the third quarter of 2013. This growth was driven by sales of its current range of self-apposing stents both directly via the Company and through its network of distribution partners in various regions around the world.

For the first nine months of the year, revenues totaled €2.8 million, up 16.9% compared with the same period of 2013.

- **A sound cash position**

At September 30, 2014, STENTYS had cash and equivalents totaling €20 million compared with €23.1 million at June 30, 2014.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, explains: "The quarterly sales growth is progressing smoothly with our current product portfolio, as illustrated by the latest success with the regional tender in the Middle East for 2015. We intend to pursue our sales coverage strategy in high-potential geographies by creating strong partnerships with the best local distributors."

- **Upcoming financial publication**

STENTYS expects to publish its 2014 full-year revenues January 22, 2015.

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS's Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. **More information is available at www.stentys.com.**

Forward Looking Statements

This press release contains forward-looking statements about the Company's business. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including